Jump to Navigation

New Schizophrenia Drug Fails Two Phase III Trials

Roche Pharmaceuticals’ potential new medication for schizophrenia, bitopertin (RG1678), failed its first two phase III trials. In both trials, adding bitopertin to antipsychotics for 24 weeks failed to improve persistent negative symptoms of schizophrenia as measured by PANSS (Positive and Negative Symptoms Scale) scores when compared to placebo, according to a report released by the company in January.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.